A Phase 3 interventional study of liraglutide and placebo in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 23 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-02-07.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 41st largest by enrollment, is one of 21 that started in 2012, is one of 45 in phase 3, and was the 57th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Mansa · Sites in United States
Ages 10+
Biolingus · Sites in Hong Kong
Ages 18–65
RenJi Hospital · Sites in China
Ages 18–65
University of Virginia · Sites in United States
Ages 21–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 46 · Phase 4 48
First in 1999; this study’s year is marked. 21 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 257 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 62 across the 151 interventional studies. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 151 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 195th largest by enrollment of the 428 interventional ones that give a count, is one of 24 that started in 2012, is one of 187 in phase 3, and was the 302nd registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing liraglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03883412University of VirginiaEffect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, from their registry updates:
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia. The purpose of the trial is to investigate the efficacy and safety of liraglutide in combination with insulin therapy compared to insulin alone in Japanese subjects with type 2 diabetes mellitus. Subjects will remain on their pre-trial insulin therapy.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 257 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: liraglutide · Drug: insulin
Drug: placebo · Drug: insulin
Liraglutide administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
Liraglutide placebo administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
All subjects will continue their pre-trial insulin therapy (basal, premixed or basal-bolus regimen) during the trial. Insulin dose is fixed for the first 16 weeks and for the subsequent 20 weeks, insulin dose is individually adjusted.
Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16
Estimated mean change from baseline in HbA1c after 16 Weeks of treatment.
Time frame: Week 0, Week 16
Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 36
Estimated mean change from baseline in HbA1c after 36 Weeks of treatment
Time frame: Week 0, Week 36
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 16
Estimated mean change from baseline in FPG after 16 Weeks of treatment.
Time frame: Week 0, Week 16
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 36
Estimated mean change from baseline in FPG after 36 Weeks of treatment.
Time frame: Week 0, Week 36
Change in Mean Plasma Glucose (PG) of 7-Point Profile From Baseline to Week 16
Estimated mean change from baseline in mean PG of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 16 Weeks of treatment.
Time frame: Week 0, Week 16
Change in Mean Plasma Glucose (PG) of 7-Point Profile From Baseline to Week 36
Estimated mean change from baseline in mean PG of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 36 Weeks of treatment.
Time frame: Week 0, Week 36
Change in Mean Prandial PG Increment of 7-Point Profile From Baseline to Week 16
Estimated mean change from baseline in mean prandial PG increment of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 16 Weeks of treatment.
Time frame: Week 0, Week 16
Change in Mean Prandial PG Increment of 7-Point Profile From Baseline to Week 36
Estimated mean change from baseline in mean prandial PG increment of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 36 Weeks of treatment.
Time frame: Week 0, Week 36
Change in Body Weight From Baseline to Week 16
Estimated mean change in body weight after 16 Weeks of treatment
Time frame: Week 0, Week 16
Change in Body Weight From Baseline to Week 36
Estimated mean change in body weight after 36 Weeks of treatment
Time frame: Week 0, Week 36
Number of Adverse Events (AEs)
An AE was defined as treatment emergent if the onset date was on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.
Time frame: Week 0 to Week 36 (inclusive)
Number of Confirmed Hypoglycaemic Episodes
A hypoglycaemic episode was defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and until the last day on randomised treatment. Confirmed hypoglycaemic episode was defined as hypoglycaemic episodes categorised to severe and/or minor hypoglycaemic episodes. Confirmed hypoglycaemia: subject unable to treat himself/herself and/or have a recorded PG \< 3.1 mmol/L (56 mg/dL). Minor: PG \< 3.1 mmol/L (56 mg/dL).
Time frame: Week 0 to week 36 (inclusive)
This trial was conducted at 23 sites in Japan.
| Milestone | Lira + Insulin | Placebo + Insulin |
|---|---|---|
| Started | 127 | 130 |
| Completed | 121 | 125 |
| Not completed | 6 | 5 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Unclassified | 4 | 3 |
Estimated mean change from baseline in HbA1c after 16 Weeks of treatment.
| percentage of glycosylated haemoglobin | Lira + Insulin | Placebo + Insulin |
|---|---|---|
| Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16 | -1.73 ± 0.06 | -0.43 ± 0.06 |
Estimated mean change from baseline in HbA1c after 36 Weeks of treatment
| percentage of glycosylated haemoglobin | Lira + Insulin | Placebo + Insulin |
|---|---|---|
| Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 36 | -1.68 ± 0.06 | -0.88 ± 0.06 |
Estimated mean change from baseline in FPG after 16 Weeks of treatment.
| mmol/L | Lira + Insulin | Placebo + Insulin |
|---|---|---|
| Change in Fasting Plasma Glucose (FPG) From Baseline to Week 16 | -1.31 ± 0.17 | -0.48 ± 0.17 |
Estimated mean change from baseline in FPG after 36 Weeks of treatment.
| mmol/L | Lira + Insulin | Placebo + Insulin |
|---|---|---|
| Change in Fasting Plasma Glucose (FPG) From Baseline to Week 36 | -1.55 ± 0.16 | -1.29 ± 0.16 |
Estimated mean change from baseline in mean PG of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 16 Weeks of treatment.
| mmol/L | Lira + Insulin | Placebo + Insulin |
|---|---|---|
| Change in Mean Plasma Glucose (PG) of 7-Point Profile From Baseline to Week 16 | -2.41 ± 0.18 | -0.53 ± 0.18 |
Estimated mean change from baseline in mean PG of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 36 Weeks of treatment.
| mmol/L | Lira + Insulin | Placebo + Insulin |
|---|---|---|
| Change in Mean Plasma Glucose (PG) of 7-Point Profile From Baseline to Week 36 | -2.65 ± 0.16 | -1.37 ± 0.16 |
Estimated mean change from baseline in mean prandial PG increment of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 16 Weeks of treatment.
| mmol/L | Lira + Insulin | Placebo + Insulin |
|---|---|---|
| Change in Mean Prandial PG Increment of 7-Point Profile From Baseline to Week 16 | -1.34 ± 0.17 | -0.61 ± 0.17 |
Estimated mean change from baseline in mean prandial PG increment of 7-point profile (7-points were before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner and at bedtime) after 36 Weeks of treatment.
| mmol/L | Lira + Insulin | Placebo + Insulin |
|---|---|---|
| Change in Mean Prandial PG Increment of 7-Point Profile From Baseline to Week 36 | -1.34 ± 0.21 | -0.94 ± 0.21 |
Estimated mean change in body weight after 16 Weeks of treatment
| kg | Lira + Insulin | Placebo + Insulin |
|---|---|---|
| Change in Body Weight From Baseline to Week 16 | -0.42 ± 0.14 | -0.28 ± 0.14 |
Estimated mean change in body weight after 36 Weeks of treatment
| kg | Lira + Insulin | Placebo + Insulin |
|---|---|---|
| Change in Body Weight From Baseline to Week 36 | 0.17 ± 0.20 | 0.52 ± 0.20 |
An AE was defined as treatment emergent if the onset date was on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.
| Events/100 years of patient exposure | Lira + Insulin | Placebo + Insulin |
|---|---|---|
| Adverse Events | 449 | 350 |
| Serious Adverse Events | 8 | 5 |
| Severe Adverse Events | 5 | 1 |
| Moderate Adverse Events | 8 | 14 |
| Mild Adverse Events | 436 | 335 |
A hypoglycaemic episode was defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and until the last day on randomised treatment. Confirmed hypoglycaemic episode was defined as hypoglycaemic episodes categorised to severe and/or minor hypoglycaemic episodes. Confirmed hypoglycaemia: subject unable to treat himself/herself and/or have a recorded PG \< 3.1 mmol/L (56 mg/dL). Minor: PG \< 3.1 mmol/L (56 mg/dL).
| Episodes/100 years of patient exposure | Lira + Insulin | Placebo + Insulin |
|---|---|---|
| Number of Confirmed Hypoglycaemic Episodes | 146 | 187 |
Collected over Adverse events were collected in a timeframe of 36 weeks + 7 days follow up.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lira + Insulin | — | 6/127 (4.7%) | 93/127 (73.2%) |
| Placebo + Insulin | — | 4/130 (3.1%) | 69/130 (53.1%) |
| Event | Lira + Insulin | Placebo + Insulin |
|---|---|---|
| Angina pectorisCardiac disorders | 1/127 | 0/130 |
| CataractEye disorders | 1/127 | 0/130 |
| Macular fibrosisEye disorders | 1/127 | 0/130 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 1/127 | 0/130 |
| Brain stem thrombosisNervous system disorders | 1/127 | 0/130 |
| Carotid artery stenosisNervous system disorders | 1/127 | 0/130 |
| HypertensionVascular disorders | 1/127 | 0/130 |
| Acute myocardial infarctionCardiac disorders | 0/127 | 1/130 |
| PneumoniaInfections and infestations | 0/127 | 1/130 |
| Cerebral infarctionNervous system disorders | 0/127 | 1/130 |
| Event | Lira + Insulin | Placebo + Insulin |
|---|---|---|
| NasopharyngitisInfections and infestations | 55/127 | 40/130 |
| ConstipationGastrointestinal disorders | 15/127 | 2/130 |
| DiarrhoeaGastrointestinal disorders | 15/127 | 4/130 |
| NauseaGastrointestinal disorders | 14/127 | 7/130 |
| Diabetic retinopathyEye disorders | 9/127 | 13/130 |
| HeadacheNervous system disorders | 8/127 | 6/130 |
| HypertensionVascular disorders | 8/127 | 6/130 |
| DyspepsiaGastrointestinal disorders | 7/127 | 0/130 |
| GastroenteritisInfections and infestations | 4/127 | 7/130 |
| Back painMusculoskeletal and connective tissue disorders | 6/127 | 7/130 |
| Age, Continuous(years) | Lira + Insulin | Placebo + Insulin | Total |
|---|---|---|---|
| Mean | 61.3 ± 11.0 | 59.8 ± 11.3 | 60.5 ± 11.2 |
| Sex: Female, Male(Participants) | Lira + Insulin | Placebo + Insulin | Total |
|---|---|---|---|
| Female | 58 | 55 | 113 |
| Male | 69 | 75 | 144 |
| Body Weight(kg) | Lira + Insulin | Placebo + Insulin | Total |
|---|---|---|---|
| Mean | 67.7 ± 15.2 | 65.9 ± 13.0 | 66.8 ± 14.1 |
| Fasting Plasma Glucose (FPG)(mmol/L) | Lira + Insulin | Placebo + Insulin | Total |
|---|---|---|---|
| Mean | 8.51 ± 2.42 | 8.79 ± 2.51 | 8.65 ± 2.47 |
| Glycosylated Haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | Lira + Insulin | Placebo + Insulin | Total |
|---|---|---|---|
| Mean | 8.8 ± 0.9 | 8.8 ± 0.9 | 8.8 ± 0.9 |
Ran from Apr 2012 to primary completion in Nov 2012, 6 months.
Results were first posted in May 2014, 1 year 6 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 6 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide